CA
PTLA

Clearstead Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Clearstead Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,500
Closed -$11K – 852
2020
Q1 		$11K Buy
+1,500
New +$18.7K ﹤0.01% 571

Other funds holding PTLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Clearstead Advisors's PTLA Position: Q2 2020 in Review

Clearstead Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 1,500 shares — an estimated $11K sold.

Clearstead Advisors first reported a position in PTLA in Q1 2020 and held it in 1 quarter. The position peaked at $11K in Q1 2020. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

  • Clearstead Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Clearstead Advisors sold 1,500 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $11K.
  • Clearstead Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • Clearstead Advisors's Portola Pharmaceuticals, Inc. position peaked at $11K in Q1 2020.
  • 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Clearstead Advisors's 13F filing for Q2 2020, filed 11 Aug 2020.